drugset / Trial / NCT04592666
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study
Timeline
- Start
- 2020-10-09
- Primary completion
- 2021-12-31
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |